Sucrazide

• Hypoglycemic Agents
• ATC:A10BB07

• Aldiab
• Apamid
• Digrin
• Dipazide
• Glibenese
• Glibetin
• Glican
• Glide
• Glidiab
• Glipid
• Glipizida [Inn-Spanish]
• Glipizide Extended-Release Tablets
• Glipizidum [Inn-Latin]
• Gluco-Rite
• Glucolip
• Glucotrol
• Glucotrol Xl
• Glucozide
• Glupitel
• Glupizide
• Glyde
• Glydiazinamide
• Melizide
• Metaglip
• Mindiab
• Minidab
• Minidiab
• Minodiab
• Napizide
• Ozidia
• Sucrazide

• No information avaliable

C₂₁H₂₇N₅O₄S

http://www.rxlist.com/cgi/generic/glip.htm

Sucrazide FDA

Sucrazide MSDS

Ambrogi, Logemann, U.S. Pat. 3,669,966 (1972)

444.548 g/mol

208-209 ^oC

37.2 mg/L

Solid

1.763

Immediate-release oral tablets; Extended-release oral tablets

For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.

Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide.

Gastrointestinal absorption is uniform, rapid, and essentially complete.

The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia.

Glipizide is a sulfonylurea used in patients with diabetes mellitus to lower blood sugar. Notify your physician if you are pregnant or nursing. Do not change the dose or stop taking glipizide without talking with your physician. Immediate-release glipizide tablets should be taken on an empty stomach, 30 minutes before a meal. Extended-release glipizide tablets may be taken with food. Do not break, crush, or chew extended-release glipizide tablets. Patients taking extended release glipizide tablets may notice something that looks like a tablet in their stool. This is the leftover tablet after the medicine has been absorbed and is normal. Avoid drinking alcohol while taking this medication. Alcohol may cause flushing, weakness, dizziness, a tingling sensation and headache. Avoid taking aspirin with this medication. Notify your physician if you develop unexplained fever, sore throat, yellowing of the skin or eyes, dark urine, or skin rash. Notify your physician if you develop fatigue, nausea, confusion, agitation, excessive hunger, profuse sweating, numbness or tingling of lips, tongue or extremities (may indicate low blood sugar), or if you develop excessive thirst or urination, or glucose or ketones in the urine or blood (may indicate high blood sugar).

Humans and other mammals